Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6Sarcoma 1

Conditions

Leukemia 11Prostatic Neoplasms 9Breast Neoplasms 9Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neuroblastoma 6Myelodysplastic Syndromes 6Multiple Myeloma 6Melanoma 6Lymphoma 6Glioblastoma 6Ovarian Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Glioma 4Osteosarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms, Male 3Neoplasms, Plasma Cell 2Neoplasms 2Medulloblastoma 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Glioblastoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT02078648 2025-02-03

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Stemline Therapeutics, Inc.

Phase 1/2 Completed
74 enrolled 19 charts
CNS

Glioblastoma

NCT02465268 2025-01-14

ATTAC-II

University of Florida

Phase 2 Completed
175 enrolled 18 charts
CNS

Glioblastoma, Glioma

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Case Comprehensive Cancer Center

Phase 2 Completed
41 enrolled 15 charts
CNS

Glioblastoma

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated
6 enrolled 7 charts
CNS

Glioblastoma, Tetanus

NCT03615404 2021-01-28

ATTAC-P

Duke University

Phase 1 Completed
11 enrolled 7 charts
CNS

Astrocytoma, Glioblastoma, Glioma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡